Business ❯ Pharmaceuticals ❯ Drug Development
International Licensing BioNTech Heart Disease Glenmark Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) China-Originated Drugs International Partnerships Immune-mediated Diseases Multiple Sclerosis Zaltenibart
The $340 million upfront payment strengthens Omeros’ cash position, with Novo targeting Phase 3 PNH trials after closing.
